Figure 1. *In vitro* adenoviral gene transduction efficiencies in murine (LM8) and human (NOS-2, U2OS and SaOS) osteosarcoma cells. Tumor cells were infected with Ad.LacZ at various multiplicity of infection (MOI), followed by X-Gal staining. Adenoviral gene transduction efficiency in each tumor cell line at each MOI is shown (A). Representative pictures of SaOS (B), NOS-2 (C) and LM8 (D) cells at an MOI of 300 showed 100, 100 and 0.25% of adenoviral gene transduction efficiency, respectively. Original magnification x40.

the IL-2 gene and not the Ad doses, Ad.dE1.3, which contains no therapeutic gene, was used as a control and for adjusting the total Ad dose up to 1×10^8 pfu in all four Ad groups. All experiments were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Research Committee of Kurume University.

Adenoviral gene transduction efficiency in vivo. To evaluate the adenoviral gene transduction efficiency in tumors *in vivo* and the distribution of Ad around tumors and in other distant organs, Ad.LacZ (1×10^8 pfu) was injected into the subcutaneous tumor at 1 day after intravenous injection of LM8 cells. Three days later, mice were sacrificed, and the subcutaneous tumor, lung, liver, spleen and kidney were harvested to assess LacZ gene expression. Tumors and these organs were frozen in Tissue-Tek® OCT compound (Sakura, Torrance, CA), and sections were fixed in PBS containing 2% formaldehyde and 0.2% glutaraldehyde for 30 min. The sections were washed 3 times with PBS and assayed for ß-galactosidase activity by incubating the slides in X-Gal staining solution.

Assessment of therapeutic and adverse effect. To assess the therapeutic effect in primary tumors, we measured each tumor periodically and calculated its volume using the following formula: volume = long axis x (short axis)^2 x 0.5236

(28). Mice were sacrificed at 28 days after an Ad injection, and histologic examination was performed.

To analyze inhibitory effects on metastases in distant organs, the lung, liver, spleen and kidney were collected from each mouse at the time of sacrifice (at 28 days after Ad injection). First, metastases in these organs were carefully estimated by macroscopic observation. Subsequently, these tissues were fixed in 10% buffered-formalin, embedded in paraffin, cut into 4-µm samples and stained with hematoxylin and eosin, and then histopathological analysis was performed. For analyses of lung metastases, the number of nodules was microscopically counted in 200 fields under magnification x100.

To estimate adverse side effects, the lung, liver, spleen and kidney were collected from each mouse at the time of sacrifice (28 days after Ad injection). In another experiment, these organs were collected at 3 days after Ad injection on the same schedule as is shown in Fig. 2. The histopathological findings of these tissues were scrupulously observed and estimated under microscopy, and the degrees of injuries in these organs were scored.

IL-2 enzyme-linked immunosorbent assay (ELISA). Blood was collected from all mice that had received primary and metastatic osteosarcoma on the same schedule as is shown in Fig. 2, at 3 days after Ad injection into the primary tumor, and serum was obtained by centrifugation of blood at

**Measurement of primary tumor size**

Figure 2. Schedule of animal experiments. LM8 cells were injected subcutaneously (s.c.) and intravenously (i.v.) in mice on days 0 and 6 to generate primary and metastatic tumors, respectively. Each Ad was injected only into the primary tumor on day 7. Mice were sacrificed on day 10 (a) for analyzing *in vivo* adenoviral gene transduction efficiency (Fig. 3), the histopathology of the primary tumor and distant organs (Fig. 6 and Table I) and serum IL-2 levels (Fig. 7). In another experiment, mice (n=5 in each group) that had received an inoculation of tumor cells and Ad injection on the same schedule were sacrificed on day 35 (b) for macroscopically and microscopically analyzing primary and metastatic tumors and other distant organs (Figs. 4 and 5), following macroscopic measurement of primary tumor size every 4 or 5 days (Fig. 4A).

3,000 rpm for 10 min. Serum mouse IL-2 levels were measured by ELISA according to the manufacturer's protocol (Cytoscreen®, BioSource International, Inc., Camarillo, CA). Briefly, serum and standards in which the IL-2 concentration had been predetermined were transferred and incubated in the wells, which were coated with an antibody specific for mouse IL-2, followed by the addition of a biotinylated second antibody. After incubation and the removal of excess second antibody, Streptavidin-peroxidase was added and the samples were incubated. After the samples were washed to

remove unbound enzyme, a substrate reaction was added, leading to the production of color. We used a plate reader to measure the absorbance of serum samples and standards at 450 nm, and we calculated the IL-2 concentration from the plotted standard curve.

Results

Low adenoviral gene transduction efficiency in tumor in vitro and in vivo. In vitro adenoviral gene transduction efficiency in LM8 cells was extremely low, and it was only 0.25% at an MOI of 300, at which adenoviral gene transduction efficiency was 100% in all three human osteosarcoma cells, that is, NOS-2, U2OS and SaOS cells (Fig. 1).

An intratumoral injection resulted in predominant gene transduction in connective tissues adjacent to tumors while less than 1% of tumor cells in a tumor nodule received transgene (Fig. 3A). The potential leak of Ad from tumor cells did not result in significant distribution of gene transduction in other distant organs, that is, there was almost none in the kidney, lung and spleen and there were less than 1% of hepatocytes in the liver (Fig. 3B-D).

Growth inhibition of the primary tumor. We generated a good syngeneic and clinical-relevant animal model for not only correctly assessing the effects of immunomodulatory therapy but also exploring our hypotheses, using highly metastatic and non-immunogenic LM8 cells, in which adenoviral gene transduction efficiency was extremely low. The growth of primary tumors was suppressed to various degrees in all three groups of mice receiving different dosages of Ad.IL-2 (Fig. 4A). Interestingly, the best outcome was obtained only when the medium dose of Ad.IL-2


Figure 3. *In vivo* adenoviral gene transduction efficiencies in tumor and distant organs by Ad.LacZ injection into subcutaneous tumor nodules in mice. Representative pictures of an X-Gal-stained primary tumor (A) showing predominant gene transduction in a small portion of the tumor and connective tissues adjacent to the tumor nodule (e, epidermis; c, connective tissues in dermis and subcutaneous tissue; t, tumor). Less than 1% of hepatocytes were X-Gal positive (B), but no apparent X-Gal-positive cells were seen in the spleen (C) or lung (D). Original magnification x40 (A) and x200 (B-D).

Figure 4. Therapeutic effect in primary tumors. Tumor growth was inhibited in mice that were treated with Ad.IL-2, and the best outcome was seen in the case of using the medium dose (3×10^7 pfu) (A). H&E-stained histology sections of primary tumor lesion in mice at 28 days after Ad injection (on day 35) showed prominent tumor death and remarkable infiltration of inflammatory cells in mice treated with 1×10^7 pfu of Ad.IL-2 (C and E). In contrast, minimal tumor cell death and no apparent infiltration of inflammatory cells were seen in mice that were treated with Ad.dE1.3 (B and D) (e, epidermis; c, connective tissues in dermis and subcutaneous tissue; t, tumor). Original magnification was x40 (B and C) and x200 (D and E).

(3×10^7 pfu) was administered. This inhibitory effect was significantly diminished when the 3-fold lower dose of Ad.IL-2 (1×10^7 pfu) was used. In addition, notably, a higher dose of Ad.IL-2 (1×10^8 pfu) did not result in further enhancement but rather diminished the inhibitory effect on primary tumors.

In contrast to absence of a necro-inflammatory reaction in any of the control mice (Fig. 4B and D), the primary tumor lesion in mice receiving Ad.IL-2 injection histologically exhibited prominent tumor cell death and marked infiltration of various kinds of inflammatory cells, including lymphocytes, granulocytes and macrophages, in the remaining tumor

Figure 5. Therapeutic effects in distant organs. Macroscopic pictures (A and B) and H&E-stained microscopic sections (C and D) of lung tissue at 28 days after Ad injection into the primary tumor are shown. The lung was widely and diffusely invaded by many metastatic nodules consisting of osteosarcoma cells in control mice that were treated with Ad.dE1.3 (A and C). Such metastases were strongly inhibited in mice treated with 3×10^7 pfu of Ad.IL-2 (B and D). Original magnification x100 (C and D). Morphometric analyses of metastases in distant organs (E and F). The percentages of mice, in which tumor nodules were macroscopically recognized in each distant organ, are shown (E). Numbers of tumor nodules in the lung was microscopically counted in 200 fields under magnification x100 (F). In both analyses, the best outcome was seen in mice that received an injection of 3×10^7 pfu of Ad.IL-2 into the primary tumor.

cells or in connective tissues adjacent to the primary tumor (Fig. 4C and E).

A dramatic inhibition of metastases in other distant organs. In contrast to the high incidence of disseminated metastases in control mice (Fig. 5A and C), metastases in distant organs were significantly suppressed by an injection of Ad.IL-2 only into the primary tumor in treated mice (Fig. 5B, D and E). The best outcome was seen when the medium dose of Ad.IL-2 (3×10^7 pfu) was injected into the primary tumor, showing no macroscopically recognized metastasis in the

lung, liver or kidney, as an inhibitory effect for metastases was completely consistent with that for the primary tumor in each Ad.IL-2-treated group.

Important and encouraging findings are that the inhibitory effect for lung metastasis was very strong in all groups of mice receiving Ad.IL-2, including the lowest dose of Ad.IL-2 (1×10^7 pfu), by which the inhibitory effect for the primary tumor was moderate. Both the number and the size of microscopically recognized tumor nodules in the lungs of mice receiving Ad.IL-2 were significantly smaller than those in control mice (Fig. 5F).

Table I. Injuries of major organs after intratumoral Ad injection.

Group	Liver		Spleen		Kidney		Lung	
	3 days	4 weeks	3 days	4 weeks	3 days	4 weeks	3 days	4 weeks
Ad.IL-2 (pfu)								
3.0x10^8	++~+++	ND	+++	ND	-	ND	+	ND
1.0x10^8	+	+	++	-	-	-	-	-
3.0x10^7	±	-	-	-	-	-	-	-
1.0x10^7	±	-	-	-	-	-	-	-
Ad.dE1.3	±	-	-	-	-	-	-	-
Vehicle	-	-	-	-	-	-	-	-

Degrees of injuries: +++, severe; ++, moderate; +, mild; ±, no apparent injury but mild inflammation; -, intact. ND, not determined because of death of mice.

Adverse side effects. Kidneys were not apparently damaged in any of the mice, including Ad.IL-2-treated mice. While lung damage was not significant at 3 days or at 28 days after 1x10^8 pfu or less than 1x10^8 pfu of Ad.IL-2 was administered into primary tumors, some of the mice treated with 3x10^8 pfu of Ad.IL-2 showed a moderate degree of interstitial pneumonia at 3 days after Ad injection, consisting of infiltration of inflammatory cells in swollen alveoli (Table I).

In contrast, the liver and spleen apparently showed severe damage at 3 days after an injection of a high dose of Ad.IL-2 (1x10^8 pfu or 3x10^8 pfu) into the primary tumor (Fig. 6 and Table I). Mice receiving the highest dose (3x10^8 pfu) of Ad.IL-2 showed that submassive hepatocyte death with marked infiltration of various kinds of inflammatory cells. The liver damage in mice receiving 1x10^8 pfu of Ad.IL-2 was somewhat milder but still apparent, while mice receiving 3x10^7 pfu or 1x10^7 pfu of Ad.IL-2 or 1x10^8 pfu of Ad.dE1.3 revealed a very mild necro-inflammatory reaction in the liver. Notably, all inflammatory reactions and damage to the liver were much milder in all mice at 28 days than those at 3 days, and even mice receiving an injection of 1x10^8 and 3x10^7 pfu of Ad.IL-2 revealed very mild and almost no apparent necro-inflammatory reaction in the liver, respectively, at 28 days after Ad injection.

The spleen was also severely damaged at 3 days after an injection of 3x10^8 pfu or 1x10^8 pfu of Ad.IL-2 into the primary tumor, histologically showing that the structure was deteriorated, and a necrotic area was widely seen in the white pulp. On the other hand, the spleen injury was not apparent when 3x10^7 pfu or 1x10^7 pfu of Ad.IL-2 was injected. Interestingly, these injured spleens were almost completely restored to normal tissue and no apparent necrotic area was seen at 28 days after an injection of any dosage, including 3x10^8 pfu, of Ad.IL-2.

Thus, the liver and spleen were the main injured organs at an acute phase, however, such inflammatory reaction and injuries were remarkably diminished and tissue was restored relatively quickly once mice survived.

Serum IL-2 levels. Increases in serum IL-2 levels were well parallel to increases in the administered dose of Ad.IL-2 into the primary tumor. The serum IL-2 levels were 1.9±2.0 and 0.3±0.4 ng/ml when 1x10^8 and 3x10^7 pfu of Ad.IL-2 were injected into the primary tumor, respectively (Fig. 7). Thus, around 0.3 ng/ml and at least 1.9 ng/ml of serum IL-2 levels may be the indicative levels for achieving the best clinical outcome and for inducing severe side effects, respectively, in this mouse model.

Discussion

This is the first report that not only describes Ad.IL-2 gene therapy for osteosarcoma but also reveals novel and crucial concepts for successful cytokine gene therapy.

The first concept that we revealed is that disseminated micro-metastases in distant organs may be feasibly treatable by an injection of Ad.IL-2 into the primary tumor without any troublesome treatment directly in metastatic tumors. The present approach to the treatment of a primary lesion of osteosarcoma is potentially useful in terms of low invasiveness and improved quality of life as well as being therapeutically effective. The loss of limbs or joints resulting from traumatic surgical resection of a primary tumor largely degrades the quality of life in osteosarcoma patients, especially in children (29,30). Furthermore, the potential therapeutic effects for the treatment of metastatic tumors in distant organs, emerging from treatment of the primary tumor, are rather attractive in terms of treatment for life-threatening disorders. Patients whose primary tumor is controlled by conventional treatment may subsequently encounter and suffer from disseminated lung metastases, for which current therapy is less effective, and to which efficient gene trans-duction is not feasible using current vector systems. In contrast, even some of the tumor cells remaining at the primary site after IL-2 gene therapy may be treatable or controllable by current therapies if the inhibition of lung metastasis can be ensured. Thus, while the therapeutic effect

Liver   **Spleen**

Figure 6. Representative histology pictures of liver and spleen at 3 days after an injection of Ad.IL-2 or Ad.dE1.3 into the primary tumor. All specimens were stained with H&E. White pulp (w) in the spleen was severely deteriorated in mice treated with 3×10^8 or 1×10^8 pfu of Ad.IL-2. Original magnification x200 (liver) and x100 (spleen).


Figure 7. IL-2 levels in serum. Blood was collected at 3 days after an injection of each Ad into the primary tumor, and IL-2 levels in serum were measured by ELISA.

on the primary tumor is beneficial, the more substantial role of the primary tumor in the present strategy is as the target site where Ad encoding cytokine gene is feasibly accessed and where it can exert a systemic antitumoral immune reaction efficiently, leading to subsequent eradication of micro-metastasis in distant organs. Such a clear concept has not yet emerged, and forms a clinical viewpoint, this is quite unique and meaningful.

The second concept and of greatest importance here is our novel finding of the optimal therapeutic expression level of IL-2 (i.e., not the highest one) needed for successful IL-2 gene therapy in terms of not only minimizing side effects but also eliciting the maximal therapeutic effect. It is likely that the vector dose administered previously was determined based only on the desire to cause minimal side effects and not from the viewpoint of obtaining the optimal cytokine level to confer antitumoral immunity most effectively. One might ingenuously recommend an increased

vector dose encoding the cytokine gene to the toleration level with respect to side effects in animals or in human patients. The present study clearly showed that only the optimal therapeutic expression level of IL-2 could induce the systemic antitumoral immunity most effectively and reveal the maximal therapeutic effects.

In addition, both the liver and spleen were minimally or severely damaged when the optimal or more than the optimal dose of Ad.IL-2 was used, respectively. Immunological mechanisms of IL-2-induced antitumoral immune reaction, with which the present pathological findings are consistent, have been well elucidated and are not the focus or the aim of the present study. We have already shown that CD4+ and CD8+ T cells and macrophages and/or natural killer cells mainly infiltrate tumor lesions and that tumor-specific CD8+ cytotoxic T cells especially play an important role in eliciting an antitumoral immune reaction after IL-2 gene therapy alone or in combination with suicide gene therapy (1,2,4). We, rather, chose IL-2 as a therapeutic gene in the present study because immunological mechanisms of IL-2 have been extensively investigated and elucidated. Despite extensive immunological analyses, actual clinical outcomes have led to unsatisfactory results, which is due to insufficient analyses and assessments from the clinical viewpoint. In this regard, more important and substantial finding in the present study is the injury in splenic white pulp, which is normally composed of B and T lymphocytes and other immune effector cells. This may be due to the disorganization of these immune effector cells by too high a concentration of circulating IL-2, because the injury to the spleen was not apparent when the optimal dose of Ad.IL-2 that elicited the maximal therapeutic effect was used. Thus, the present pathological findings indicate that the spleen may play an important role in IL-2 gene therapy and spleen injuries may result in the diminished therapeutic effect seen with the higher than optimal dose of Ad.IL-2. Moreover, we found that liver and spleen injuries were recoverable, and, notably, that severe damage in the spleen was almost normalized within a month. These findings are encouraging with regard to the potential safety and clinical applicability of this approach. On the other hand, the narrow range of the optimal therapeutic expression level of IL-2, i.e., only a single available dose in the present model, may be a critical issue and further emphasize the importance for successful clinical application. In this regard, we demonstrated that serum IL-2 level may be a good indicator for determining the optimal therapeutic expression level and monitoring the risk of systemic side effects, because it was consistently parallel to the administered doses of Ad.IL-2 into the primary tumor lesion and because it can be feasibly measured in human patients as well.

The third novel concept is that local and predominant secretion of a cytokine from connective tissues adjacent to a tumor instead of the tumor itself can elicit sufficient antitumoral immunity, which indicates that cytokine gene therapy does not require high gene transduction efficiency in the tumor itself, in contrast to previously held beliefs. It has been believed that inefficient gene transduction efficiency in tumors may largely limit the clinical utility of cancer gene therapy in general (31,32), and some investigators have tried to increase or target gene transduction efficiency in the

tumor itself even in the case of cytokine gene therapy (33). Obviously, the fact that any current vector cannot transduce a therapeutic gene to every cancer cell by *in vivo* administration has substantially limited the clinical utility and benefit of gene transfer of intracellular molecules (34). In fact, Ad-mediated suicide gene therapy, which exhibits the potent bystander effects for a variety of cancers (19,35-37), did not show apparent regression of primary or metastatic tumors in the present animal model (data not shown). In contrast, we clearly demonstrated that an injection of Ad.IL-2 into the primary tumor, in which gene transduction efficiencies *in vitro* and *in vivo* were extremely low, could have a sufficient therapeutic effect, as shown by the fact that local secretion of IL-2 from the connective tissue adjacent to the tumor induced a systemic antitumoral immune reaction. Because the role of gene transduction efficiency in the tumor in cytokine gene therapy has been to date overestimated or uncertain, this novel concept and contradictory finding may largely facilitate the clinical use of cytokine gene therapy and may be important for planning and developing future strategies.

Taken together, from the clinical viewpoint, all of the properties of the present strategy may allow for its clinical use for osteosarcoma patients. It is feasible that an injection of Ad.IL-2 into the primary lesion may be commonly administered to osteosarcoma patients before conventional treatments, regardless of the pre-existence, or lack thereof, of lung metastasis, as long as side effects and serum IL-2 levels are carefully monitored. Any therapeutic effects against lung metastasis, which may result from both prophylactic treatment via a cancer vaccine for sequential metastasis and regression of tumor growth of pre-existent metastasis, would be beneficial for osteosarcoma patients, even though Ad.IL-2 gene therapy alone cannot completely cure them.

In conclusion, just a single injection of the optimal dose of Ad.IL-2, presumably Ad encoding some cytokine genes as well, only into the primary lesion may be clinically useful in terms of feasibility, low invasiveness, cost effectiveness as well as therapeutic potential for disseminated metastatic cancers. More generally and importantly, we have revealed novel concepts that have been missing but crucially necessary for successful cytokine gene therapy, that is, the optimal therapeutic expression levels of a cytokine, the fact that high gene transduction efficiency in the tumor itself is unnecessary and the strategy of treating only the primary tumor in order to eradicate metastatic tumors without any direct treatment to the latter.

Acknowledgements

References

1. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS and Woo SL: Combination gene therapy for liver metastasis of colon carcinoma *in vivo*. Proc Natl Acad Sci USA 92: 2577-2581, 1995.
2. Huang H, Chen SH, Kosai K, Finegold MJ, and Woo SL: Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy *in vivo*. Gene Ther 3: 980-987, 1996.
3. Caruso M, Pham-Nguyen K, Kwong YL, *et al*: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 93: 11302-11306, 1996.
4. O'Malley BW Jr, Sewell DA, Li D, Kosai K, Chen SH, Woo SL and Duan L: The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 11: 667-673, 1997.
5. Kwong YL, Chen SH, Kosai K, Finegold M and Woo SL: Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer. Chest 112: 1332-1337, 1997.
6. Moller GT: T cell stimulating growth factors. Immunol Rev 51: 1-357, 1980.
7. Fearon ER, Pardoll DM, Itaya T, *et al*: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990.
8. Henney CS, Kuribayashi K, Kern DE and Gillis S: Interleukin-2 augments natural killer cell activity. Nature 291: 335-338, 1981.
9. Lotze MT, Grimm EA, Mazumder A, Strausser JL and Rosenberg SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420-4425, 1981.
10. Trinchieri G: Biology of natural killer cells. Adv Immunol 47: 187-376, 1989.
11. Smith KA: Interleukin-2: inception, impact, and implications. Science 240: 1169-1176, 1988.
12. Parmiani G, Rivoltini L, Andreola G and Carrabba M: Cytokines in cancer therapy. Immunol Lett 74: 41-44, 2000.
13. Marshall E: Cancer therapy. Setbacks for endostatin. Science 295: 2198-2199, 2002.
14. Galanis E and Russell S: Cancer gene therapy clinical trials: lessons for the future. Br J Cancer 85: 1432-1436, 2001.
15. McCormick F: Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 1: 130-141, 2001.
16. Kiwaki K, Kanegae Y, Saito I, *et al*: Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Hum Gene Ther 7: 821-830, 1996.
17. Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I and Wilson JM: Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 271: 3639-3646, 1996.
18. Lehrman S: Virus treatment questioned after gene therapy death. Nature 401: 517-518, 1999.
19. Fukunaga M, Takamori S, Hayashi A, Shirouzu K and Kosai K: Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model. Ann Thorac Surg 73: 1740-1746, 2002.
20. Terazaki Y, Yano S, Yuge K, *et al*: An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice. Hepatology 37: 155-163, 2003.
21. Papagelopoulos PJ, Galanis EC, Vlastou C, *et al*: Current concepts in the evaluation and treatment of osteosarcoma. Orthopedics 23: 858-867, 2000.
22. Dome JS and Schwartz CL: Osteosarcoma. Cancer Treat Res 92: 215-251, 1997.
23. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E and Solheim OP: Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 75: 1084-1093, 1995.
24. Bacci G, Briccoli A, Ferrari S, *et al*: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 37: 2030-2039, 2001.
25. Marina NM, Pratt CB, Rao BN, Shema SJ and Meyer WH: Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 70: 2722-2727, 1992.
26. Bacci G, Briccoli A, Ferrari S, *et al*: Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 7: 339-346, 2000.
27. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S and Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 76: 418-422, 1998.
28. Ko SC, Gotoh A, Thalmann GN, *et al*: Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 7: 1683-1691, 1996.
29. Greenberg DB, Goorin A, Gebhardt MC, Gupta L, Stier N, Harmon D and Mankin H: Quality of life in osteosarcoma survivors. Oncology 8: 19-35, 1994.
30. Lane JM, Christ GH, Khan SN and Backus SI: Rehabilitation for limb salvage patients: kinesiological parameters and psychological assessment. Cancer 92: 1013-1019, 2001.
31. Pandha HS, Martin LA, Rigg AS, Ross P and Dalgleish AG: Gene therapy: recent progress in the clinical oncology arena. Curr Opin Mol Ther 2: 362-375, 2000.
32. Smith AE: Gene therapy - where are we? Lancet 354 (Suppl. 1): SI1-S4, 1999.
33. Okada Y, Okada N, Nakagawa S, *et al*: Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Lett 177: 57-63, 2002.
34. Gomez-Navarro J, Curiel DT and Douglas JT: Gene therapy for cancer. Eur J Cancer 35: 2039-2057, 1999.
35. Bonnekoh B, Greenhalgh DA, Bundman DS, *et al*: Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer *in vivo* for treatment of experimental human melanoma. J Invest Dermatol 106: 1163-1168, 1996.
36. Kwong YL, Chen SH, Kosai K, Finegold MJ and Woo SL: Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer. Cancer Gene Ther 3: 339-344, 1996.
37. Block A, Chen SH, Kosai K, Finegold M and Woo SL: Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 15: 25-34, 1997.

A Definitive Role of RhoC in Metastasis of Orthotopic Lung Cancer in Mice

Tetsuro Ikoma,[1,2] Tomoyuki Takahashi,[2]
Satoshi Nagano,[2,4] Yun-Mo Li,[1] Yasushi Ohno,[1]
Kazuki Ando,[3] Takako Fujiwara,[6]
Hisayoshi Fujiwara,[1] and Ken-ichiro Kosai[2,4,5]

[1]Department of Cardiology, Respiratory and Nephrology, Regeneration and Advanced Medical Science, Graduate School of Medicine, Gifu University, and Departments of [2]Gene Therapy and Regenerative Medicine and [3]Gastroenterology and Hematology, Pathophysiology and Regulatory Medical Sciences, Gifu University School of Medicine, Gifu and [4]Division of Gene Therapy and Regenerative Medicine, Cognitive and Molecular Research Institute of Brain Diseases, Kurume University, and [5]Department of Pediatrics, Kurume University School of Medicine, Kurume; and [6]Department of Food Science, Kyoto Women's University, Kyoto, Japan

ABSTRACT

Purpose: Lung cancer is a major cause of cancer death, and its incidence is increasing in the world. Conventional therapies remain less effective for metastases of lung cancer, leading to poor prognosis of this disorder. The present study investigates pathological roles of RhoC in metastasis of lung cancer using a clinically relevant mouse model of lung cancer.

Experimental Design: RhoA, RhoC, dominant-negative Rho (dnRho) or green fluorescent protein gene was retrovirally transduced to murine lung cancer cells. For *in vivo* study, these transduced cells were intrapulmonary inoculated in syngeneic mice, and subsequently, growth and metastasis were analyzed. Migration and invasion activities were further investigated by *in vitro* chemotaxic chamber assays. Expression levels and activities of certain matrix metalloproteinases (MMPs) were explored by reverse transcription-PCR and gelatin zymography.

Results: Metastasis of lung cancer in the animal model, as well as *in vitro* migration and invasion, were significantly enhanced or inhibited by overexpression of RhoC or dnRho, respectively, without affecting the growth of primary tumors. Expression levels of certain MMPs and the activity of MMP-2 were significantly enhanced or suppressed by overexpression of RhoC or dnRho, respectively.

Conclusion: RhoC plays a crucial role in metastasis of lung cancer. RhoC does not affect tumor growth but enhances the metastatic nature of lung cancer by not only stimulating cell motility but also up-regulating certain MMPs. Attenuation of RhoC activity may be a potential target in the development of a novel strategy for treating metastasis of lung cancer.

INTRODUCTION

Lung cancer is the leading cause of cancer death and accounted for 28% of all cancer death in the United States (1–3). The 5-year survival rate for all lung cancer patients remains only 10–15% in the United States, and the incidence of lung cancer continues to increase in the world (1, 3). About 80% of lung cancers are non-small cell lung carcinoma (NSCLC). The current therapies, including chemotherapy and radiotherapy, are less effective for NSCLC; the response rates in NSCLC remain <50%, and complete regression is rare (4). On the other hand, small cell lung carcinoma has a more highly metastatic nature than NSCLC, leading to a 5-year survival rate of <8% (5). Thus, the poor prognosis of lung cancer, including small cell lung carcinoma and NSCLC, indicates an urgent need for the development of innovative therapies for treating lung cancer (6, 7).

In general, prognoses of cancer patients, including cases of NSCLC and small cell lung carcinoma, deeply correlate with their clinical stages, which reflect the degree of metastasis to regional lymph nodes and distant organs, as well as the expansion of the primary tumor (1), *e.g.*, lung cancer patients diagnosed with stage IV disease have a 2-year survival rate of <20% (1, 3). Thus, an inhibition of metastasis is a potential useful target in the development of a novel therapeutic strategy for treating cancer. From the biological viewpoint, tumor invasion and metastasis represent a complex process, in which numbers of molecules may be involved, and some crucial factors and mechanisms remain to be solved (8). Authors of a recent study using DNA arrays implied that several genes involved in extracellular matrix assembly or actin-based cytoskeletal reorganization might play an important role in the metastasis of melanoma cells (9). Furthermore, this study showed that RhoC might modulate the metastatic nature of melanoma (9). These findings encourage us to investigate the pathological role of RhoC in metastasis of lung cancer.

RhoC GTPase is a member of the Ras-homology family of small GTP-binding proteins and responsible for actin cytoskeletal reorganization during cellular motility (10, 11). Relatively small numbers of studies on RhoC and cancer have been reported to date, although molecular mechanisms of RhoC-dependent cytoskeletal organization have been extensively investigated from the biological viewpoint (10, 12). The involvement of RhoC has been implicated in only limited types of cancers, such as melanoma (9), inflammatory breast cancer

(13, 14), ovarian cancer (15), and ductal adenocarcinoma of the pancreas (16), but no study has yet been reported regarding RhoC and lung cancer. More importantly, all previous reports describing RhoC and cancer, including those just cited, focus solely on cell motility as the mechanism in RhoC-dependent enhancement of cancer metastasis (9). In the present study, we investigated the pathological role of RhoC using the clinically relevant mouse model of lung cancer, and a novel mechanism of RhoC in cancer metastasis, which is that RhoC apparently up-regulates matrix metalloproteinases (MMPs).

MATERIALS AND METHODS

Cell Lines. The murine lung cancer cell line Lewis lung cancer (LLC) was purchased from American Type Culture Collection (Rockville, MD) and cultured in 5% CO_2 at 37°C in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, and 100 μg/ml streptomycin.

Reverse Transcription-PCR. Total RNA was extracted from LLC cells using Sepazol RNA I super kit (Nacalai Tesque, Inc., Kyoto, Japan) according to the manufacturer's protocol. For reverse transcription-PCR analysis, 1 μg of total RNA was reverse transcribed using SuperScript II reverse transcriptase (Invitrogen Corp., Carlsbad, CA), and then 1/100 of the cDNA was subjected to PCR amplification by 38 cycles of 94°C for 30 s, each annealing temperature for 1 min and 72°C for 1 min using the primer sets described previously (16–18). Annealing temperatures were 58°C for *RhoA* and *RhoC* genes; 55°C for *MMP-2, MMP-9,* and *membrane-type* (*MT*) *1-MMP* genes; and 45°C for the *tissue inhibitors of metalloproteinase* (*TIMP*)-2 gene. The *hypoxanthine-guanine phosphoribosyltransferase* gene was amplified as an internal control with the same cycle and temperature as was used for each target gene using the following primer set: (a) sense 5'-CCTGCTGGATTACATTA-AAGCACTG-3'; and (b) antisense 5'-AAGGGCATATCCAA-CAACAA-3'. The amplified cDNA was electrophoresed on 2% agarose gel containing ethidium bromide. The reproducibility of the results was confirmed by three independent experiments.

Retroviral Vectors and Gene Transduction. The retroviral vector plasmids pMIG-RhoA, pMIG-RhoC, pMIG-N19RhoA (a kind gift from Dr. R. Hynes), and pMX-green fluorescent protein (GFP; a kind gift from Dr. T. Kitamura) were transfected to the 293T cell-derived ecotropic retroviral packaging cell line Phoenix (a kind gift from Dr. G. Nolan) to produce retroviral vectors that express RhoA, RhoC, dnRho and enhanced GFP, *i.e.*, RV-RhoA, RV-RhoC, RV-dnRho, and RV-GFP, respectively (9, 19, 20). Supernatant containing each retroviral vector was collected at 48, 60, and 72 h after transfection and was used for three rounds of retroviral infection with LLC cells (21). Retroviral gene transduction efficiencies and transgene expressions were confirmed by flow cytometric analysis (FACStar; Becton Dickinson, Bedford, MA) of RV-GFP-infected cells and reverse transcription-PCR analysis of each transgene.

Animal Studies. Female C57BL/6 mice at 6–8 weeks old were purchased from Japan Slc, Inc. (Hamamatsu, Japan) and housed in cages in a temperature-controlled room on a 12-h light-dark cycle with free access to food and water. All animal studies were performed in accordance with the NIH guidelines

as dictated by the Animal Care Facility at the Gifu University School of Medicine.

Mice received a percutaneous and intrapulmonary inoculation of the transfected LLC cells as described previously with some modification (6, 22). Briefly, after a small incision had been made in the skin on the left chest wall, a 29-gauge needle attached to a 0.5-ml syringe was directly inserted into the left lung at a depth of 3 mm, whereas the animal was under ether anesthesia. Subsequently, 1×10^3 retrovirally infected LLC cells mixed with Matrigel basement membrane matrix (Becton Dickinson) were injected into the left lung. The animals were sacrificed at 10, 14, and 21 days after tumor implantation; the sizes of primary tumors in the lung were measured, and the mediastinal lymph nodes were weighed. The volume of the primary tumor was calculated using the formula ½ × (long diameter) × (short diameter)^2.

Histopathology and Immunohistochemistry. Tissues were fixed in 10% formalin and embedded in paraffin, and 4-μm sections were stained with H&E to evaluate the morphology. For immunohistochemistry, 6-μm frozen sections were fixed in 4% paraformaldehyde and stained with rabbit anti-GFP antibody (Molecular Probes, Inc., Eugene, OR), Alexa Fluor 488-conjugated antirabbit IgG (Molecular Probes, Inc.), and Hoechst 33342 (Molecular Probes, Inc.).

In Vitro **Cell Migration and Invasion Assays.** Cell migration and invasion assays were performed using 8-μm pore size Transwell Biocoat Control inserts and Biocoat Matrigel invasion chambers (Becton Dickinson), respectively, according to the manufacturer's protocol. In brief, 5×10^4 retrovirally transduced LLC cells were seeded on a transwell containing numbers of 8-μm pores covered with or without a thin layer of Matrigel basement membrane matrix for invasion or migration assay, respectively, which was set on a 24-well plate. Cells on the top surface of the transwell were removed by scrubbing 24 h after incubation, and the remaining cells on the bottom surfaces of the membrane were fixed and stained using Diff-Quick staining kit (International Reagents Corp., Kobe, Japan). Such invaded and migrated cells were counted and compared among groups. Individual experiments were done in duplicate and repeated four times.

Gelatin Zymography. Gelatin zymography was performed using a Gelatinzymo electrophoresis kit (Yagai Research Center, Yamagata, Japan) according to the manufacturer's protocol. In brief, 2.5×10^5 cells were seeded onto 10-cm dishes and incubated for 24 h in the serum-containing media. The cells were then rinsed twice and incubated in serum-free media for an additional 24 h. After the collected supernatants were centrifuged to remove contaminated cells and debris, they were mixed with sample buffer and electrophoresed on a 10% SDS-polyacrylamide gel containing 2.5 mg/ml gelatin. The gel was washed and incubated in reaction buffer for an additional 36 h at room temperature. It was then stained with Coomassie Blue and subsequently immersed with destaining buffer for 3 h.

Statistic Analysis. Statistical significances between a control group (parental LLC cells) and each of the treatment groups (retrovirally transduced LLC cells) were determined using the unpaired Student *t* test. $P < 0.05$ was considered to have statistical significance.

Fig. 1 Retroviral gene transduction and expressions of Rho family genes. A, endogenous mRNA levels in Lewis lung cancer (LLC) cells by reverse transcription (RT)-PCR analysis. RT(+) and RT(−) indicate PCR analysis with or without reverse transcription, respectively. NT, no template as a negative control. Total RNA extracted from HepG2 cells or mouse lung tissue was used for a positive control of PCR assay. Hypoxanthine-guanine phosphoribosyltransferase gene was amplified as an internal control gene. B, flow cytometric (in top and center figures) and fluorescent microscopic (in the bottom figures) analyses after retroviral infections in LLC cells. The percentages of green fluorescent protein (GFP)-positive cells after one, two, or three rounds of infection with RV-GFP are shown in the top figure. The center figures show the intensities and numbers of GFP-positive cells that received three rounds of infection with RV-GFP and those of parental LLC cells without any retroviral infections. The LLC cells after three rounds of infection with RV-GFP were also observed under the phase contrast and fluorescent microscopy (the bottom figures). C, mRNA expression levels of transgenes after three rounds of retroviral infection in LLC cells.

RESULTS

Retroviral Gene Transduction and Expressions of Rho Family Genes. Reverse transcription-PCR analysis demonstrated that parental LLC cells endogenously expressed RhoA, RhoB, and RhoC at relatively low levels (Fig. 1A). A flow cytometric analysis demonstrated that a single infection with RV-GFP resulted in 56% gene transduction efficiency in LLC cells (Fig. 1B). Two or three rounds of retroviral infection further increased gene transduction efficiencies in LLC cells ≤74 or 86%, respectively. Importantly, expression levels of transgene were various among individual cells after

three rounds of retroviral infection; this situation is similar to *in vivo* gene transduction but different from the use of artificial homogenous cloned cells. After three rounds of infection with each retroviral vector, expression of each target gene was significantly enhanced (Fig. 1C). Cells infected with RV-RhoA, RV-RhoC, and RV-dnRho expressed certain levels of GFP because pMIX plasmids comprise GFP cDNA downstream of the encephalomyocarditis virus internal ribosomal entry sequence (23). Increases in intensities of PCR bands corresponding to RhoA after RV-dnRho infections may be reasonable because the primer sets for RhoA also

A

B

C

Day 10   Day 14   Day 21

D

E

LN

Day 14   Day 21

Fig. 2 The orthotopic lung cancer model in mice. A mouse received intrapulmonary inoculation of 1×10^3 of Lewis lung cancer cells into the left lung. *A,* the representative macroscopic picture of the primary tumor (*PT*) and mediastinal lymph nodes (*LN*) 21 days after the tumor implantation. In *B,* the primary tumor volume and lymph node weight were shown. △ or ▲, the groups receiving the parental Lewis lung cancer cells without any retroviral infection or those receiving the RV-green fluorescent protein (*GFP*)-infected Lewis lung cancer cells, respectively (five mice per group). *C* and *D,* the representative microscopic pictures of the PT (*C*) and LN (*D*) 10, 14, and 21 days after the tumor implantation. H&E staining. Original magnification: ×20. In *E,* frozen sections of the PT and LN 21 days after implantation of the RV-GFP-infected Lewis lung cancer cells were stained with anti-GFP and Hoechst 33342.

have affinity to the sequence of dnRho (only substitution from Thr to Asn at codon 19 of the *RhoA* gene; Ref. 19).

Establishment of an Orthotopic Lung Cancer Model in Combination with Retroviral Gene Transduction. The primary tumor nodule in the lung parenchyma was macroscopically recognizable ∼10 days after intrapulmonary implantation of parental LLC cells, and it rapidly grew and expanded between days 14 and 21 (Fig. 2, *A* and *B*). On the other hand, metastases of tumors to mediastinal lymph nodes were not macroscopically recognizable on day 10; however, metastatic foci were conspicuous on day 14, and metastases were prom-

inent on day 21 (Fig. 2, *A* and *C*). It should be noted that there were not any differences in the growth of primary tumors, the degree of metastases to the mediastinal lymph nodes, or histological findings between RV-GFP-infected and parental LLC cells (Fig. 2*A–D*). Moreover, GFP immunohistochemistry demonstrated stable transgene expression in not only the primary tumor nodule but also metastases in the mediastinal lymph nodes on day 21 (Fig. 2*E*). Thus, retroviral gene transduction in combination with the orthotopic lung cancer model has advantages in stable transgene expression and in the lack of artificial effects relating to retroviral gene trans-

duction, which enable us to estimate actual effects of transgenes under clinically relevant conditions.

RhoC Enhanced Metastases without Affecting Primary Tumor Growth *in Vivo*. We studied the effects of Rho family genes and the dominant-negative Rho (dnRho) gene for primary tumor growth and metastasis to the mediastinum lymph nodes using this new system (Figs. 3 and 4). Interestingly, there were no differences among groups in macroscopic sizes, volumes, or histological findings of the primary tumor during the 21 days of the experiment. On the other hand, metastases to mediastinal lymph nodes were drastically increased between 14 and 21 days after tumor implantation in the case of overexpression of RhoC. In contrast, overexpression of dnRho resulted in significantly smaller sizes and weights of the mediastinal lymph nodes on day 21 compared with parental and GFP-expressing LLC cells. Overexpression of RhoA or GFP did not change the weights of the lymph nodes. It should be noted that no differences were seen in histopathological findings of the metastatic tumor among groups, including groups of RhoC- and dnRho-expressing LLC cells (Fig. 3). Thus, RhoC was largely involved in the metastatic activity of lung cancer (LLC cells) without modulating the growth or morphological change of the primary tumor.

RhoC Enhanced Activities of Both Migration and Invasion of Lung Cancer *in Vitro*. To investigate the mechanism of RhoC-dependent metastasis, we carried out *in vitro* migration and invasion assays (Fig. 5). Overexpression of RhoC enhanced migration as well as invasion, although the effect for the latter was more prominent than that for the former. In contrast, overexpression of dnRho inhibited both migration and invasion, whereas overexpression of RhoA or GFP did not affect either. These findings indicate that RhoC may regulate the metastatic nature of lung cancer not only by stimulating cell motility (probably by modulation of the cytoskeletal structure that is well known) but also by directly enhancing the invasive activity, *i.e.*, the degradation of extracellular matrix.

RhoC Enhanced the Expression and Activity of MMPs. It is well known that MMP family proteins play central roles in cancer invasion relating to enzymatic degradation of extracellular matrix. Therefore, we examined mRNA expression levels and activities of the representative MMPs to assess whether the invasive effect of RhoC may result from modulation of MMP activities (Fig. 6). Overexpression of RhoC resulted in significant increases in mRNA expressions of MMP-2, MMP-9, MT1-MMP, and TIMP-2. In contrast, overexpression of dnRho decreased mRNA expression levels of MMP-2, MMP-9, MT1-MMP, and/or TIMP-2 to some degree (prominently, those of MTP-9 and MT1-MMP) in comparison with those of control RV-GFP-infected or parental cells. Zymographic analysis further and strongly confirmed this finding; not only pro (inactive) forms of MMP-2 and MMP-9 but also the active form of MMP-2 were significantly up-regulated by overexpression of RhoC. In contrast, dnRho decreased proMMP-2 and proMMP-9, although the inhibitory effect for active MMP-2 could not be assessed in this experiment because of the absence of detectable levels of active MMP-2 in control parental LLC cells. All these results suggest that RhoC may up-regulate MMPs at the transcriptional and/or enzymatic processional levels, leading to enhancement of the invasive activity of the LLC cells.

DISCUSSION

This is the first study to reveal clearly and experimentally that specifically RhoC, but not RhoA, plays a crucial role in the metastasis of lung cancer. Previous studies implied involvement of the Rho family, including Rho (*e.g.,* RhoA, B, and C), Rac, and Cdc42 proteins, in cancer (12), but the pathological role of each of the Rho family proteins was not clear, and the overall mechanisms in Rho-dependent oncogenic effects have not yet been fully clarified. Physiological functions of these family proteins have been largely investigated; they regulate a wide variety of cell function, especially cytoskeletal reorganization during cellular motility (10, 24). Importantly and interestingly, despite the high homology of the different Rho isoforms, RhoA, RhoB, and RhoC (25, 26), their physiological roles are distinct (24). Likewise, there is a possibility that a specific type of Rho isoform may be involved in the pathogenesis of lung cancer. In clinical studies, significant increases in RhoA in head and neck squamous cell (27), upper urinary tract (28), colon (29), breast (29), and lung (29) cancer and significant increases in RhoC in breast cancer (13, 14, 30) were shown, although other Rho isoforms were not investigated in these studies. Thus far, only four studies, to our knowledge, have compared the combined expression levels of RhoA, RhoB, and RhoC in cancer of human patients. Three of the studies demonstrated significantly higher levels of both RhoA and RhoC in ovarian carcinoma (15), bladder cancer (31), and breast tumors (32) than levels in nontumor tissues. It should be noted that only one of these four studies demonstrated a significant increase in RhoC only, and not in RhoA or RhoB, in ductal adenocarcinoma of the pancreas in human patients (16).

A majority of previous experimental studies on Rho and cancer used RhoA as the representative of the Rho family or the materials that might work on several Rho family proteins; based on such results, the pathological roles of the whole Rho family in cancer have been generalized and broadly speculated (19, 20). In addition, a variety of cancer cell lines has been used without any particular reason for their investigations, and based on the results, authors have roughly speculated about the function of the Rho family in a range of cancers. As a result, only one experimental study, to our knowledge, has investigated roles of the Rho family, specifically in lung cancer (33). However, the study used C3 exoenzyme that ADP-ribosylates Rho on Asn-41, *i.e.,* that might wok on both RhoA and RhoC, leading to indistinguishable assessments regarding predominant contribution of RhoA or RhoC (33). Thus, the pathological roles of RhoC in lung cancer have not yet been well defined from clinical or experimental studies; the present study for the first time presents convincing evidence that RhoC, but not RhoA, at least in the type of murine lung cancer cells we tested, modulates the metastatic nature of lung cancer.

Accumulating data concerning biological functions of the Rho family proteins have suggested that tumorigenesis, cell cycle impairment, inhibition of apoptosis, and stimulation of invasion and metastasis may be possibly the major pathological roles of the Rho family in cancer (12). Tumorigenesis was not our focus in the present study and may be explored elsewhere. It remains to be clarified whether RhoC may confer tumorigenesis on lung tissue, because early studies revealed involvements

Fig. 3 The macroscopic and microscopic pictures of the primary and metastatic tumors in the mouse orthotopic lung cancer model. Lewis lung cancer cells (1 × 10³ cells) that were beforehand infected with each retroviral vector were intrapulmonary inoculated into a mouse. In *A*, the representative macroscopic pictures of the primary tumor (*PT*) and metastatic tumor in the mediastinal lymph nodes (*LN*) 21 days after the implantation of RV-RhoC-infected, RV-dominant-negative Rho (*dnRho*)-infected, and parental Lewis lung cancer cells were shown. *B* and *C*, the microscopic pictures of the PT (*B*) and LN (*C*). H&E staining. Original magnification: ×20, the *top* pictures and ×200, the *bottom* pictures. The mice that received RV-RhoA- or RV-green fluorescent protein-infected Lewis lung cancer cells showed similar findings to the parental control (data not shown).

Fig. 4 The primary tumor volume (*A*) and lymph node weight (*B*). The protocol of the animal experiment was described in Fig. 3. □, ◨, ●, △, and ▲, the RV-RhoA, RV-RhoC, RV-dominant-negative Rho, RV-green fluorescent protein, and parental (control) groups, respectively. Data represent means and SDs (*n* = 15–19/group). *, *P* < 0.05; **, *P* < 0.01 (Student's *t* test; each of treatment groups *versus* the parental control).

metastasis in cancer diseases, but not to the enhancement of cancer cell growth or antiapoptotic effect in cancer cells.

It is reasonable to consider that RhoC is largely involved in migration, *i.e.,* cell motility, of tumor cells, because RhoC regulates actin cytoskeletal organization, which is believed to provide the driving force for cell migration (10). On the other hand, it has been largely unclear how Rho family proteins exhibit the invasive activity, and the exact mechanism of RhoC-dependent invasion is almost unknown. The present study for the first time explored the relationship between RhoC and MMPs in cancer and clarified the novel mechanism; RhoC apparently up-regulated both expression levels and activities of MMPs, leading to enhancement of the invasive activity. We examined MMP-2, MMP-9, and MT1-MMP, as well as TIMP-2, which were the representative MMPs and their antagonist that were largely involved in invasion by a variety of

of only RhoA and other Rho family proteins in malignant transformation (19, 20, 34). On the other hand, involvements of Rho family proteins in cell cycle-related molecules and/or mitogenic signal transduction pathways have been extensively studied from biological viewpoints (10, 12). In addition, the relationship between Rho family proteins and apoptosis has recently been implicated (10, 12). Because disregulations of cell growth and cell death are the characteristic and essential nature of cancer, it has been speculated that increases in Rho proteins may be involved in the proliferation of cancer cells and/or their resistance to death signals. In the present study, however, neither the growth nor death of tumor cells in the primary tumor was affected by gene transduction of dnRho or RhoC. In contrast, overexpression of RhoC remarkably stimulated not only the metastasis of lung cancer in this clinically relevant animal model but also the activities of both migration and invasion in the *in vitro* assays. Moreover, gene transduction of dnRho inhibited the metastasis in the animal model and the activities of migration and invasion. Thus, it is likely that a number of molecules, various signal transduction pathways, and diverse biological effects relating to RhoC may mostly contribute to the activities of migration and invasion of cancer cells, *i.e.,* the

Fig. 5 *In vitro* migration (*A*) and invasion (*B*) activities. Lewis lung cancer cells received three rounds of infection with each retroviral vector as described in Fig. 1. The numbers of these cells on the bottom surface of transwell containing 8-μm pores covered with or without the Matrigel were counted as migration and invasion activities, respectively, 24 h after incubation. Data represent means and SDs of three independent experiments (*n* = 15/group in each experiment). *, *P* < 0.05; **, *P* < 0.01 (Student's *t* test; each of treatment groups *versus* the parental control).

A **Retroviral vectors**

RhoA RhoC dnRho GFP Parental NT

MMP2

MMP9

MT1-MMP

TIMP2

HPRT

B **Retroviral vectors**

marker RhoA RhoC dnRho GFP Parental

ProMMP2 → 92

ProMMP9 → 72

MMP2 → 62

Fig. 6 Expression levels and activities of matrix metalloproteinases (*MMP*) after overexpressions of the Rho family proteins. Lewis lung cancer cells were infected with each retroviral vector as described in Fig. 1. *A,* reverse transcription-PCR analysis of certain MMPs. *NT,* no template. In *B,* the retrovirally gene-transduced Lewis lung cancer cells were incubated in serum-free media for 24 h, and the supernatants were electrophoresed on a 10% SDS-polyacryl-amid gel containing 2.5 mg/ml gelatin. The gel was incubated in reaction buffer for an additional 36 h and stained with Coomassie Blue.

cancers (35), including lung cancer in human patients (35–37). In fact, a clinical study demonstrated increases in MT1-MMP mRNA expressions and activation of MMP-2 in lung cancer, including small cell lung carcinoma and NSCLC, and a high correlation of the degree of MMP-2 activation with that of MT1-MMP mRNA expression and lymph node metastases (37). In the present study, gene transduction of RhoC significantly increased mRNA levels of MMP-2, MMP-9, MT1-MMP, and TIMP-2, and it activated MMP-2; gene transduction of dnRho apparently decreased mRNA levels of MMP-9 and MT1-MMP. Such RhoC-dependent transcriptional changes in MMP genes are new and interesting findings, and the detailed mechanisms, especially the transcriptional factors linking to RhoC, may be clarified in future studies. In this regard, the finding of an increase in mRNA levels of TIMP-2, an inhibitor for MT1-MMP and MMP-2, in this study should be noted. ProMMP-2

binds MT1-MMP using TIMP-2 as an adaptor by forming a trimolecular complex on the cell surface, and another MT1-MMP near the complex cleaves the propeptide bond of proMMP-2, leading to active MMP-2 (35). Although no study has investigated the mechanism of RhoC-dependent invasion, other recent studies have shown that RhoA and Rac1 could modulate the degradation and remodeling of the extracellular matrix by regulating the levels of either MMPs or their antagonists, TIMPs (38–40). In addition, Rac1 induced lamellipodia, and the MT1-MMP was localized there; Rac1 enhanced the activation of MMP-2 (35, 38, 41). The ruffled edge that forms the migration front is likely the site of the homo-oligomer formation of MT1-MMP that augments proMMP-2 activation (35, 41). Taken together, there is a possibility that RhoC may not only transcriptionally increase MMPs' expressions but also be responsible for localization of such MT1-MMP complex to migration edge. In this regard, a recent study showing a relatively stable association of MT1-MMP with actin cytoskeleton should be noted; CD44, which associated with actin within cells, localized at the migration front and was identified as a linker that mediated the association of MT1-MMP with actin (42).

Finally, it is encouraging that therapeutic effects of dnRho gene transduction were statistically significant in this clinically relevant lung cancer model. Somewhat milder phenotype after dnRho gene transduction than that of RhoC may possibly result from a relatively low expression level of endogenous RhoC in LLC cells and/or effective but incomplete inhibition of RhoC activity by the present dnRho gene construct. Nevertheless, the present results importantly suggest that attenuation of RhoC activity may be one of the potential targets in the development of novel strategies for treating metastasis of lung cancer.

In conclusion, RhoC apparently confers a metastatic nature on lung cancer without affecting the growth of primary tumors. One of the definitive mechanisms of the RhoC-dependent metastasis is up-regulating expressions and activities of MMPs.

REFERENCES

1. Beadsmoore, C. J., and Screaton, N. J. Classification, staging and prognosis of lung cancer. Eur. J. Radiol., *45:* 8–17, 2003.

2. Colice, G. L., Rubins, J., and Unger, M. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest, *123:* 272S–283S, 2003.

3. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer Statistics, 2003. CA Cancer J. Clin., *53:* 5–26, 2003.

4. Rosell, R., Gomez-Codina, J., Camps, C., Javier Sanchez, J., Maestre, J., Padilla, J., Canto, A., Abad, A., and Roig, J. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer, *26:* 7–14, 1999.

5. Lassen, U., Osterlind, K., Hansen, M., Dombernowsky, P., Bergman, B., and Hansen, H. H. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years–an

analysis of 1,714 consecutive patients. J. Clin. Oncol., *13:* 1215–1220, 1995.

6. Fukunaga, M., Takamori, S., Hayashi, A., Shirouzu, K., and Kosai, K. Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model. Ann. Thorac. Surg., *73:* 1740–1746, 2002.

7. Kwong, Y. L., Chen, S. H., Kosai, K., Finegold, M., and Woo, S. L. Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer. Chest, *112:* 1332–1337, 1997.

8. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, *64:* 327–336, 1991.

9. Clark, E. A., Golub, T. R., Lander, E. S., and Hynes, R. O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature (Lond.), *406:* 532–535, 2000.

10. Etienne-Manneville, S., and Hall, A. Rho GTPases in cell biology. Nature (Lond.), *420:* 629–635, 2002.

11. Tapon, N., and Hall, A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr. Opin. Cell Biol., *9:* 86–92, 1997.

12. Sahai, E., and Marshall, C. J. RHO-GTPases and cancer. Nat. Rev. Cancer, *2:* 133–142, 2002.

13. van Golen, K. L., Bao, L., DiVito, M. M., Wu, Z., Prendergast, G. C., and Merajver, S. D. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol. Cancer Ther., *1:* 575–583, 2002.

14. Kleer, C. G., van Golen, K. L., Zhang, Y., Wu, Z. F., Rubin, M. A., and Merajver, S. D. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am. J. Pathol., *160:* 579–584, 2002.

15. Horiuchi, A., Imai, T., Wang, C., Ohira, S., Feng, Y., Nikaido, T., and Konishi, I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab. Investig., *83:* 861–870, 2003.

16. Suwa, H., Ohshio, G., Imamura, T., Watanabe, G., Arii, S., Imamura, M., Narumiya, S., Hiai, H., and Fukumoto, M. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br. J. Cancer, *77:* 147–152, 1998.

17. Itoh, T., Tanioka, M., Matsuda, H., Nishimoto, H., Yoshioka, T., Suzuki, R., and Uehira, M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis, *17:* 177–181, 1999.

18. Ailenberg, M., and Silverman, M. Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP). Biochem. J., *313:* 879–884, 1996.

19. Qiu, R. G., Chen, J., McCormick, F., and Symons, M. A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. USA, *92:* 11781–11785, 1995.

20. Qiu, R. G., Chen, J., Kim, D., McCormick, F., and Symons, M. An essential role for Rac in Ras transformation. Nature (Lond.), *374:* 457–459, 1995.

21. Kosai, K. I., Finegold, M. J., Thi-Huynh, B. T., Tewson, M., Ou, C. N., Bowles, N., Woo, S. L., Schwall, R. H., and Darlington, G. J. Retrovirus-mediated in vivo gene transfer in the replicating liver using recombinant hepatocyte growth factor without liver injury or partial hepatectomy. Hum. Gene Ther., *9:* 1293–1301, 1998.

22. Doki, Y., Murakami, K., Yamaura, T., Sugiyama, S., Misaki, T., and Saiki, I. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br. J. Cancer, *79:* 1121–1126, 1999.

23. Liu, X., Sun, Y., Constantinescu, S. N., Karam, E., Weinberg, R. A., and Lodish, H. F. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc. Natl. Acad. Sci. USA, *94:* 10669–10674, 1997.

24. Takai, Y., Sasaki, T., and Matozaki, T. Small GTP-binding proteins. Physiol. Rev., *81:* 153–208, 2001.

25. Yeramian, P., Chardin, P., Madaule, P., and Tavitian, A. Nucleotide sequence of human rho cDNA clone 12. Nucleic Acids Res., *15:* 1869, 1987.

26. Chardin, P., Madaule, P., and Tavitian, A. Coding sequence of human rho cDNAs clone 6 and clone 9. Nucleic Acids Res., *16:* 2717, 1988.

27. Abraham, M. T., Kuriakose, M. A., Sacks, P. G., Yee, H., Chiriboga, L., Bearer, E. L., and Delacure, M. D. Motility-related proteins as markers for head and neck squamous cell cancer. Laryngoscope, *111:* 1285–1289, 2001.

28. Kamai, T., Kawakami, S., Koga, F., Arai, G., Takagi, K., Arai, K., Tsujii, T., and Yoshida, K. I. RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int., *91:* 234–238, 2003.

29. Fritz, G., Just, I., and Kaina, B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer, *81:* 682–687, 1999.

30. van Golen, K. L., Bao, L. W., Pan, Q., Miller, F. R., Wu, Z. F., and Merajver, S. D. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin. Exp. Metastasis, *19:* 301–311, 2002.

31. Kamai, T., Tsujii, T., Arai, K., Takagi, K., Asami, H., Ito, Y., and Oshima, H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res., *9:* 2632–2641, 2003.

32. Fritz, G., Brachetti, C., Bahlmann, F., Schmidt, M., and Kaina, B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer, *87:* 635–644, 2002.

33. Tokman, M. G., Porter, R. A., and Williams, C. L. Regulation of cadherin-mediated adhesion by the small GTP-binding protein Rho in small cell lung carcinoma cells. Cancer Res., *57:* 1785–1793, 1997.

34. Khosravi-Far, R., Solski, P., Clark, G., Kinch, M., and Der, C. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol., *15:* 6443–6453, 1995.

35. Seiki, M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett., *194:* 1–11, 2003.

36. Lim, M., and Jablons, D. M. Matrix metalloproteinase expression in lung cancer. Methods Mol. Med., *74:* 349–356, 2003.

37. Tokuraku, M., Sato, H., Murakami, S., Okada, Y., Watanabe, Y., and Seiki, M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int. J. Cancer, *64:* 355–359, 1995.

38. Zhuge, Y., and Xu, J. Rac1 mediates type I collagen-dependent MMP-2 activation: role in cell invasion across collagen barrier. J. Biol. Chem., *276:* 16248–16256, 2001.

39. Engers, R., Springer, E., Michiels, F., Collard, J. G., and Gabbert, H. E. Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression. J. Biol. Chem., *276:* 41889–41897, 2001.

40. Matsumoto, Y., Tanaka, K., Harimaya, K., Nakatani, F., Matsuda, S., and Iwamoto, Y. Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn. J. Cancer Res., *92:* 429–438, 2001.

41. Itoh, Y., Takamura, A., Ito, N., Maru, Y., Sato, H., Suenaga, N., Aoki, T., and Seiki, M. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J., *20:* 4782–4793, 2001.

42. Mori, H., Tomari, T., Koshikawa, N., Kajita, M., Itoh, Y., Sato, H., Tojo, H., Yana, I., and Seiki, M. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J., *21:* 3949–3959, 2002.

20 Matsuoka N, Nozaki K, Takagi Y, *et al*. Adenovirus-mediated gene transfer of fibroblast growth factor-2 increases BrdU-positive cells after forebrain ischemia in gerbils. *Stroke* 2003; **34**: 1519–1525

21 Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? *Lancet Oncol* 2003; **4**: 415–422

22 Rainov NG, Ren H. Gene therapy for human malignant brain tumors. *Cancer J* 2003; **9**: 180–188

23 Dai Y, Schwarz EM, Gu D, *et al*. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. *Proc Natl Acad Sci USA* 1995; **92**: 1401–1405

24 Ohmoto Y, Wood MJ, Charlton HM, *et al*. Variation in the immune response to adenoviral vectors in the brain: Influence of mouse strain, environmental conditions and priming. *Gene Ther* 1999; **6**: 471–481

25 Akli S, Caillaud C, Vigne E, *et al*. Transfer of a foreign gene into the brain using adenovirus vectors. *Nature Genet* 1993; **3**: 224–228

26 Davidson BL, Allen ED, Kozarsky KF, *et al*. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. *Nature Genet* 1993; **3**: 219–223

27 Dewey RA, Morrissey G, Cowsill CM, *et al*. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. *Nat Med* 1999; **5**: 1256–1263

28 Kielian T, Hickey WF. Inflammatory thoughts about glioma gene therapy. *Nat Med* 1999; **5**: 1237–1238

29 Principles of Laboratory Animal Care formulated by the National Society for Medical Research

30 Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resource. NIH Publication No. 86-23, revised 1985

31 Chen SH, Chen XH, Wang Y, *et al*. Combination gene therapy for liver metastasis of colon carcinoma in vivo. *Proc Natl Acad Sci USA* 1995; **92**: 2577–2581

32 Terazaki Y, Yano S, Yuge K, *et al*. An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice. *Hepatology* 2003; **37**: 155–163

33 Cruz JI, Loste JM, Burzaco OH. Observations on the use of medetomidine/ketamine and its reversal with atipamezole for chemical restraint in the mouse. *Lab Anim* 1998; **32**: 18–22

34 Byrnes AP, Rusby JE, Wood MJ, *et al*. Adenovirus gene transfer causes inflammation in the brain. *Neuroscience* 1995; **66**: 1015–1024

35 Perry VH, Andersson PB, Gordon S. Macrophages and inflammation in the central nervous system. *Trends Neurosci* 1993; **16**: 268–273

36 Lowenstein PR, Castro MG. Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: Peculiarities, mechanisms, and consequences. *Gene Ther* 2003; **10**: 946–954

37 Ghodsi A, Stein C, Derksen T, *et al*. Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. *Hum Gene Ther* 1998; **9**: 2331–2340

38 Driesse MJ, Esandi MC, Kros JM, *et al*. Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. *Gene Ther* 2000; **7**: 1401–1409

39 Lieberman AP, Pitha PM, Shin HS, *et al*. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. *Proc Natl Acad Sci USA* 1989; **86**: 6348–6352

40 Selmaj K, Raine CS, Farooq M, *et al*. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. *J Immunol* 1991; **147**: 1522–1529

41 Shamash S, Reichert F, Rotshenker S. The cytokine network of Wallerian degeneration: Tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. *J Neurosci* 2002; **22**: 3052–3060

42 Selmaj KW, Farooq M, Norton WT, *et al*. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. *J Immunol* 1990; **144**: 129–135

43 McMenamin PG. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. *J Comp Neurol* 1999; **405**: 553–562

44 Serdar M. Periventricular lucency on computed tomography associated with hydrocephalus: What is the cause? *Surg Neurol* 1995; **44**: 285–286

Regenerative Medicine

Ⅰ．ヒトおよびサルのES細胞

ES細胞再生医学の新技術開発
―ヒトES細胞と遺伝子治療技術―

A novel biotechnology for embryonic stem cell-based regenerative medicine

Keywords

- ヒトES細胞
- 遺伝子治療
- アデノウイルスベクター
- 心筋分化
- 再生医学

高橋 知之 [1)2)3)]　藤原 久義 [4)]

國貞 隆弘 [5)]　小戝健一郎 [1)3)6)]

1）久留米大学高次脳疾患研究所 遺伝子治療再生医学
2）久留米大学医学部 創薬再生医療学
3）岐阜大学医学部 遺伝子治療再生医科学
4）岐阜大学大学院再生医科学 循環器病態学
5）岐阜大学大学院再生医科学 組織・器官形成
6）久留米大学医学部 小児科学

Summary

The successful use of pluripotent embryonic stem (ES) cells for regenerative medicine is currently hampered by both the insufficiency of tissue-specific differentiation and the difficulty of distinctly purifying target cells. In addition, it is more difficult to induce tissue-specific differentiation of human ES cells than that of mouse ES cells. We found that the formation of embryoid bodies, which is the most popular method for inducing cardiomyogenic differentiation of mouse ES cells, did not work in human ES cells; we, thus, developed a novel co-culture system to solve this issue. We found that the conventional method that expressed a marker gene under a cell-specific promoter did not always work for identifying ES cell-derived target cell. We, thus, developed the novel biotechnology that efficiently identified any ES cell-derived target cells. This article describes these methods and discusses the usefulness of gene therapy vectors for ES cell-based regenerative medicine.

Takahashi, Tomoyuki [1)2)3)] / Fujiwara, Hisayoshi [4)] / Kunisada, Takahiro [5)] / Kosai, Ken-ichiro [1)3)6)]

1) Division of Gene Therapy and Regenerative Medicine, Cognitive and Molecular Research Institute of Brain Diseases, Kurume University
2) Department of Advanced Therapeutics and Regenerative Medicine, Kurume University School of Medicine
3) Department of Gene Therapy and Regenerative Medicine, Gifu University School of Medicine
4) Division of Cardiology, Respiratory and Nephrology, Regeneration and Advanced Medical Science, Graduate School of Medicine, Gifu University
5) Division of Regeneration of Organ and Tissue Development, Regeneration and Advanced Medical Science, Graduate School of Medicine, Gifu University
6) Department of Pediatrics and Child Health, Kurume University School of Medicine
E-mail : kosai@med.kurume-u.ac.jp

はじめに

　近年流行の再生医療（医学）は，「主に生物学的な知見の応用と技術により，傷害・疾病で失われた組織を補完する治療法」（の研究）の総称であり，その個々の内容，対象疾患ともさまざまである。大きく分類すれば，生体内で組織を再生誘導する「生体内再生療法」[1)-5)]，体外で目的の細胞／組織を創り移植する「再建療法」[6)] の二戦略であり，前者ではその再生誘導物質と方法，後者ではソースとなる細胞種と技術に，研究の特色がある。また，骨髄（幹）細胞による，造血器以外の臓器疾患への再生医療は，「手技が簡単で，自家移植（あるいは体内で誘導）[7)]」という臨床化しやすい点から近年注目を浴びているが，その治療メカニズムや効率はいまだ不明確であるため，現時点では別分類として論じるべきであろう。

さて，後者の再建療法において，目的細胞を創る主なソースは，体性幹細胞とES（胚性幹）細胞である。体性幹細胞は患者本人の細胞を自家移植するという点で，免疫拒絶が起こらないという長所がある一方，医療として採取可能で，大量培養もでき実際に利用可能な体性幹細胞は現時点では限られている。一方，ES細胞には受精胚から作製という生命倫理の問題がある一方，ほとんどの組織，細胞に in vitro でも分化誘導できる多能性という潜在能力，多量培養可能な能力という点から，臓器移植に代わる再建療法での基盤ソース細胞として期待されている[6)8)]。ES細胞による再建医療の実現には，①目的細胞を効率よく分化誘導する方法，②目的細胞を同定・単離する技術，③細胞移植治療法の確立，の全3段階で技術を開発，確立する必要がある。しかし，現在のES細胞を用いた再生医学の研究は，従来型の発生学研究，すなわち分化現象の研究にやや偏っているように思われる。筆者らも「発生学」研究の成果は最重要と考える一方で，併せて再生「医学」研究として①～③の各段階の技術開発も同様に重要と考えている。本稿では再生医学研究の意義を踏まえながら，心筋細胞をモデルとした①②における筆者らの開発した技術，特に「遺伝子治療技術のES細胞への導入」，「ヒトES細胞での研究」について概説する。

生体内再生療法

生後も再生能を保持している肝臓，皮膚，血管，造血器などの疾患（よって移植のための組織採取が，これらの臓器では可能なわけである）には，筆者らは，ES細胞再建療法よりも「生体内再生療法」の開発の方が理想的だと思っている（もちろん，ES細胞の研究が不必要ということではない）。たとえば筆者らは，効果的な治療法がないためいまだ70％の致死率の劇症肝炎に対し，肝栄養因子のHGF（肝細胞増殖因子）による根治的治療法を開発した[1)2)4)]。これはHGFの肝細胞への強力な抗アポトーシス作用で（前段階の急性肝障害からの）劇症肝炎の発症を阻止すると同時に，生体内で強力に肝再生を誘導して[3)9)]，障害肝も治癒していくという，理想的な治療法となる生体内再生療法である。さらに筆者らは最近，肝栄養因子のHB-EGF（ヘパリン結合EGF様増殖因子）が，HGFより強力に肝障害抑制と肝再生誘導作用を示すことを見い出し，より効果的な劇症肝炎治療法となるHB-EGF生体内肝再生療法を開発した[10)11)]。

また，治療手技という点では，急性疾患には組み換え蛋白質の投与でも十分であろうが，慢性疾患に対しては，1回の治療で治療因子を長期発現できる遺伝子治療が，より効果的な治療法となる可能性が高い。たとえばHGF遺伝子治療は，肝障害と肝線維化の阻止と肝再生の促進から肝硬変を治療で

き[12)]，さらに肝硬変に合併しやすい肝癌へは抑制（治療）作用を示す[13)]。このように医療法の開発という点を重視すれば，再生能を保持する肝臓の疾患では，このような遺伝子治療・生体内再生療法の開発が，（少なくとも現時点では）より有効で現実的かもしれない。

一方，筆者らは，HGF，可溶性Fas受容体，可溶性TGFβⅡ受容体などの遺伝子治療（アデノウイルスベクターの1回の骨格筋への注射）で，心筋梗塞後のリモデリングの病態が改善できるという成果を得ている[14)～16)]。これはこのような遺伝子治療が難治性心疾患へも有用な治療法となることを示す有望な結果である一方で，肝臓の場合とは異なり欠損した心筋細胞は生体内で再生治癒することはないため，「自律再生能のない臓器の疾患には，遺伝子治療単独では根治となる生体内再生療法にはなりがたい」という限界も示している。よって生後は再生能を失う，心臓，脳神経，その他多くの臓器の疾患の治療には，ES細胞による再建療法の開発が併せて必要となるものである。

ES細胞の in vitro 分化誘導法

ES細胞の in vitro 分化誘導法としては，①初期胚を模倣した胚様体の作製，②分化誘導因子の添加，③フィーダー細胞との共培養，あるいは④目的とする組織・細胞の分化にかかわる転写因子を強制的に発現するなどさまざまな方法が試みられている[8)17)]。